Rubius Therapeutics Inc (NASDAQ:RUBY)’s stock price was up 8.2% during trading on Wednesday . The company traded as high as $9.08 and last traded at $9.02, approximately 259,578 shares traded hands during mid-day trading. A decline of 29% from the average daily volume of 364,968 shares. The stock had previously closed at $8.34.

A number of equities analysts recently commented on RUBY shares. BidaskClub upgraded Rubius Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. JPMorgan Chase & Co. downgraded Rubius Therapeutics from an “overweight” rating to a “neutral” rating and set a $9.00 price objective on the stock. in a report on Friday, January 31st. Zacks Investment Research downgraded Rubius Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Rubius Therapeutics in a report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $17.40.

The business has a fifty day moving average of $8.82 and a 200 day moving average of $9.65. The stock has a market cap of $687.89 million, a price-to-earnings ratio of -4.63 and a beta of 2.31. The company has a debt-to-equity ratio of 0.30, a current ratio of 9.83 and a quick ratio of 9.83.

Rubius Therapeutics (NASDAQ:RUBY) last released its quarterly earnings data on Thursday, November 14th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.06). During the same period in the previous year, the business posted ($0.42) earnings per share. On average, analysts expect that Rubius Therapeutics Inc will post -2.04 EPS for the current year.

In other Rubius Therapeutics news, insider Christopher L. Carpenter sold 48,000 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $13.48, for a total transaction of $647,040.00. Following the transaction, the insider now owns 82,843 shares in the company, valued at $1,116,723.64. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 58.40% of the company’s stock.

A number of hedge funds have recently made changes to their positions in RUBY. Cubist Systematic Strategies LLC increased its position in Rubius Therapeutics by 29.3% in the fourth quarter. Cubist Systematic Strategies LLC now owns 17,789 shares of the company’s stock worth $169,000 after purchasing an additional 4,031 shares during the period. Marshall Wace LLP acquired a new stake in Rubius Therapeutics in the fourth quarter worth about $111,000. Bank of New York Mellon Corp increased its position in Rubius Therapeutics by 11.6% in the fourth quarter. Bank of New York Mellon Corp now owns 139,785 shares of the company’s stock worth $1,328,000 after purchasing an additional 14,530 shares during the period. Goldman Sachs Group Inc. increased its position in Rubius Therapeutics by 36.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 91,610 shares of the company’s stock worth $871,000 after purchasing an additional 24,589 shares during the period. Finally, UBS Group AG increased its position in Rubius Therapeutics by 273.7% in the fourth quarter. UBS Group AG now owns 37,222 shares of the company’s stock worth $354,000 after purchasing an additional 27,261 shares during the period.

About Rubius Therapeutics (NASDAQ:RUBY)

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

See Also: Quantitative Easing

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.